- Home
- NGNE
NGNE
Neurogene Inc.
as 03-31-2025 1:41pm EST
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $59.80 | AVG Volume (30 days): | 219.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.47 - $74.49 | Next Earning Date: | 03-24-2025 |
| Revenue: | $925,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Neurogene Inc. (NGNE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cvijic Christine Mikail | NGNE | President and CFO | Mar 13 '25 | Sell | $16.94 | 4,501 | $76,246.94 | 72,343 |
Latest Neurogene Inc. News
NGNE Breaking Stock News: Dive into NGNE Ticker-Specific Updates for Smart Investing
Business Wire
7 days ago
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
Business Wire
a month ago
Neurogene to Participate in Upcoming Conferences
Simply Wall St.
a month ago
Neurogene Insiders Placed Bullish Bets Worth US$1.46m
Argus Research
4 months ago
Daily – Vickers Top Buyers & Sellers for 11/27/2024
Business Wire
4 months ago
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
Investor's Business Daily
4 months ago
How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week
Business Wire
4 months ago
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Investor's Business Daily
5 months ago
Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal
Compare NGNE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NGNE Neurogene Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.